BioSpace News Archive

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021

Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the first quarter of its fiscal year 2021, which ended June 30, 2020. First quarter and recent operational highlights include: Clearance from Health Canada and the U.S. FDA to initiate Appili’s Phase

KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company participated in a mid-cycle communication meeting on August 13, 2020, with the U.S. Food and Drug Administration (FDA) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of attention deficit hype

Two Additional Orphan Drug Designations Granted for OCU400 Modifier Gene Therapy Program Conference Call and Webcast Today at 8:30 a.m. ET

Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase Successful public equity offering, private placement with Pfizer Inc., and CARB-X grant provide significant funding to advance lead product candidates YONKERS, New York, Aug. 14, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and develop

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced yesterday financial and operating results for the quarter ended June 30, 2020. SECOND QUARTER 2020 FINANCIAL RESULTS The Company reported total revenue from continuing operations of $1.4 million for the second quarter of 2020 compared to revenue of $1.5 million in the second quarter of 2019, a

StageZero Life Sciences today announced that it will release its Second Quarter 2020 operational results after market close on Friday, August 14, 2020.

Company successfully completes warrant repricing and exchange, with gross proceeds to total $10.5 million Company Enters Negotiation for Potential Licensing of Neuropathies Asset

Spectral Medical Inc., (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2020. Financial Review Revenue for the three-months ended June 30, 2020 was $517,000 compared to $1,041,000 for the same three-month period last year. For the six-months ended June 30, 2020, revenue was $1,148,000 compared to $1,588,000 in the

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that it has entered into an agreement with a South Korean manufacturer of rapid diagnostic tests, for U.S. distribution rights to its propr